samedan logo
home > white papers > Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products - Entegris


phone +1 978 436 6500
web http://
email 129 Concord Road, Billerica, MA 01821

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.

Many pharmaceuticals — monoclonal antibodies, vaccines, and patient-specific therapeutics — must be reliably stored and transported at sub-zero temperatures, requiring a robust cold chain that contin ues throughout downstream processing (Figure 1). Demand for these pharmaceutical products is on the order of hundreds of kilograms per year and contin ues to increase.1 While large manufacturers are already well-equipped to handle these volumes, it is possible for smaller laboratories to quickly adapt to produce a wide variety of specialized drugs and distribute them without compromising safety or increasing financial risk.
Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

Member login

E-mail address:

Remember me

News and Press Releases

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform

 Dundee, UK, 14th December 2021 – Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.
More info >>

White Papers

Optimize your Biologic’s Analytical Program for Greater Risk Reduction


Analytical methods are used throughout upstream and downstream processes to help ensure the desired molecule is being produced with the desired purity. In addition to having the right molecule, quality must be confirmed in terms of glycosylation, oxidation, aggregates, activity and concentration. The analytical package must also ensure that all impurities from the manufacturing process and environment are consistently removed.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement